Takeda delivers resilient FY2020 financials

11 May 2021

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) today announced financial results for fiscal year 2020 (period ended March 31, 2021), which the company says demonstrate its “resilient portfolio.”

Reported revenues at 3,197.8 billion yen (~$28.9 billion), declined by 2.8% impacted primarily by foreign exchange and divestitures. Underlying revenues growth in FY2020 was +2.2% driven by the growth of Takeda’s 14 global brands, up 16% year-on-year

Takeda delivered reported operating profit of 509.3 billion yen (~$4.6 billion), which grew 407.2% with gains from non-core asset sales and acquisition-related expenses. Core operating profit, which adjusts for purchase price accounting (PPA) and non-recurring items (including gains on sales of assets), increased year-on-year to JPY 967.9 billion yen (~$8.8 billion). Takeda’s reported net profit was 376 billion yen, a 749.9% increase compared with the same period in the prior year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK